Successful immunisation and safety shown in Vacc-4x/Endocine study
Bionor Pharma, Eurocine Vaccines and University of Oslo Hospital have revealed that vaccine-related immune responses are documented in patients given active vaccine in a nasal immunisation study, combining Bionor's Vacc-4x and Eurocine's adjuvant Endocine. Dose-related differences are currently under evaluation, and additional data including antibody production in mucosal secretions will be analysed and published at a later stage. The results also document safety by nasal administration of the vaccine. The clinical costs have been covered by a grant from the Research Council of Norway (RCN) of US$1.2 million (NKr 6.9 million), under the GLOBVAC programme.
Vacc-4x is a therapeutic HIV vaccine based on four, slightly modified peptides (building blocks of proteins) from conserved parts of the HIV virus. Endocine is an adjuvant shown to enhance the immune response to vaccine antigens delivered nasally. Researchers at University of Oslo Hospital studied the effect of nasal delivery of Vacc-4x in combination with Endocine, compared with the effect of Endocine alone.